topicAmla Lipid Profile Meta-Analysis
claim1–3 Hyperglycemia and type 2 diabetes mellitus (T2DM) are significant risk for cardiovascular diseases (CVD) in individuals with hypercholesterolemia, potentially leading to coronary artery disease, stroke, and other complications.
evidence level4
citationMichel P. Hermans (2024)
sourcePotential synergistic antihyperglycemic effects of co-supplemental Amla and Olive extracts in hyperlipidemic adults with prediabetes and type 2 diabetes: results from a real-life clinical study
topicAmla Lipid Profile Meta-Analysis
claimAlthough statin therapy lowers low-density lipoprotein cholesterol (LDL-C) and reduces CVD risk, it is associated with an increased risk of incident prediabetes and T2DM ().
evidence level4
citationMichel P. Hermans (2024)
sourcePotential synergistic antihyperglycemic effects of co-supplemental Amla and Olive extracts in hyperlipidemic adults with prediabetes and type 2 diabetes: results from a real-life clinical study
topicAmla Lipid Profile Meta-Analysis
claimElevated blood glucose levels in hyperlipidemic individuals are linked to insulin resistance, oxidative stress, subclinical inflammation, and lipotoxicity, which heighten the risk of T2DM and its complications, including cardiovascular outcomes, neuropathy, nephropathy, and retinopathy.
evidence level4
citationMichel P. Hermans (2024)
sourcePotential synergistic antihyperglycemic effects of co-supplemental Amla and Olive extracts in hyperlipidemic adults with prediabetes and type 2 diabetes: results from a real-life clinical study